Combination of pembrolizumab with radiotherapy can change treatment paradigm in metastatic “non‐driver” non‐small‐cell lung cancer: assembling a path

2021 ◽  
Author(s):  
Farkhad Manapov ◽  
Chukwuka Eze ◽  
Julian Taugner ◽  
Benedikt Flörsch ◽  
Lukas Käsmann
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Treatment Paradigm

scholarly journals Managing Patients With Relapsed Small-Cell Lung Cancer

2018 ◽  
Vol 14 (6) ◽  
pp. 359-366 ◽  
Author(s):  
Jun Gong ◽  
Ravi Salgia
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Sequential Therapy ◽  
Initial Therapy ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Treatment Paradigm

Despite high response rates to initial therapy, relapses are common in patients with small-cell lung cancer (SCLC). Systemic therapy after first-line failure remains important in the treatment paradigm of SCLC. Reinitiation of a previously administered first-line chemotherapy regimen is recommended for relapse > 6 months from completion of initial therapy. For relapse ≤ 6 months of initial therapy, sequential therapy with single agents is recommended. Clinical trial enrollment should be considered at all stages of treatment of SCLC. This review highlights the available treatment options in relapsed SCLC. In particular, we focus on prospective clinical trials demonstrating activity for the most commonly used agents in this setting. We end with a discussion on future directions and emerging targets with potential to improve outcomes in relapsed SCLC.

scholarly journals New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?

2021 ◽  
pp. 1-10
Author(s):  
Bingnan Zhang ◽  
Samuel R. Birer ◽  
Mikhail Dvorkin ◽  
Jolly Shruti ◽  
Lauren Byers
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Treatment Options ◽  
Current Treatment ◽  
Small Cell ◽  
Personalized Treatment ◽  
Small Cell Lung ◽  
Treatment Standards ◽  
Treatment Paradigm

Small cell lung cancer (SCLC) is an aggressive form of lung cancer with a 5-year survival rate of less than 7%. In contrast to non–small cell lung cancer, SCLC has long been treated as a homogeneous disease without personalized treatment options. In recent years, the incorporation of immunotherapy into the treatment paradigm has brought moderate benefit to patients with SCLC; however, more effective therapies are urgently needed. In this article, we describe the current treatment standards and emerging therapeutic approaches for the treatment of SCLC. We also discuss promising biomarkers in SCLC and the recently discovered four subtypes of SCLC, each with its unique therapeutic vulnerability. Lastly, we discuss the advances in radiation therapy for the treatment of SCLC.

Sign in / Sign up

Export Citation Format

Share Document